**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 62034

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study**

Maddalena C *et al*. Sarcopenia in mCRC

Chiara Maddalena, Andrea Ponsiglione, Luigi Camera, Lidia Santarpia, Fabrizio Pasanisi, Dario Bruzzese, Camilla Panico, Giovanni Fiore, Simona Camardella, Tolomeo Caramia, Alessia Farinaro, Sabino De Placido, Chiara Carlomagno

**Chiara Maddalena, Lidia Santarpia, Fabrizio Pasanisi, Giovanni Fiore, Simona Camardella, Tolomeo Caramia, Alessia Farinaro, Sabino De Placido, Chiara Carlomagno,** Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples 80131, Italy

**Andrea Ponsiglione, Luigi Camera, Camilla Panico,** Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples 80131, Italy

**Dario Bruzzese,** Department of Public Health, University of Naples Federico II, Naples 80131, Italy

**Author** **contributions:** Maddalena C contributed to the conception and design of the study, acquisition of data, analysis and interpretation of data, and writing the original draft; Ponsiglione A and Panico C contributed to the analysis and interpretation of data; Camera L, Santarpia L and Pasanisi F contributed to the conception and design of the study; Bruzzese D contributed to the biostatistical analysis; Fiore G, Camardella S, Caramia T and Farinaro A contributed to the acquisition of data; De Placido S contributed to the supervision; Carlomagno C contributed to the conception and design of the study, analysis and interpretation of data, supervision, review and editing, and final approval of the version of the article to be published.

**Corresponding author: Chiara Maddalena, MD, Academic Fellow,** Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Naples 80131, Italy. chiara.maddalena@yahoo.it

**Received:** December 26, 2020

**Revised:** January 31, 2021

**Accepted:** March 18, 2021

**Published online:** May 24, 2021

**Abstract**

BACKGROUND

Sarcopenia is a condition characterized by decreased skeletal muscle mass due to physiological ageing or to a concomitant disease such as neoplasia. In cancer patients, a low lean body mass is suggested to be a negative prognostic factor for survival and for the development of dose-limiting chemotherapy toxicities irrespective of disease stage.

AIM

To evaluate the prognostic role of sarcopenia in patients with metastatic colorectal cancer (mCRC) undergoing first-line chemotherapy.

METHODS

Our retrospective analysis included 56 mCRC patients who received first-line chemotherapy from 2014 to 2017 at the Medical Oncology Unit of our hospital. Computerized scans were performed before starting chemotherapy and at the first disease reassessment. Sarcopenia was assessed using the skeletal mass index = muscle area in cm2/(height in m2) calculated at the L3 vertebra. Overall survival and objective response rate were evaluated. Toxicities were analyzed during the first four cycles of therapy and graded according to Common Terminology Criteria for Adverse Events version 4.0. A loss of skeletal muscle mass ≥ 5% was considered indicative of deterioration in muscle condition.

RESULTS

Median age was 67 years and 35.7% of patients were ≥ 70 years old. Fourteen patients (25%) were sarcopenic at baseline computed tomography (CT) scan (7/33 men; 7/23 women); 5/14 sarcopenic patients were ≥ 70 years old. Median follow-up was 26.8 mo (3.8-66.8 mo) and median overall survival was 27.2 mo (95%CI: 23.3-37.3). Sarcopenia was not correlated to overall survival (*P* = 0.362), to higher toxicities reported during the first 4 cycles of chemotherapy (*P* = 1.0) or to response to treatment (*P* = 0.221). At the first disease reassessment, a skeletal muscle loss (SML) ≥ 5% was found in 17 patients (30.3%) 3 of whom were already sarcopenic at baseline CT scan, while 7 patients became sarcopenic. SML was not correlated to overall survival (*P* = 0.961). No statistically significant correlation was found between baseline sarcopenia and age (*P* = 1.0), body mass index (*P* = 0.728), stage at diagnosis (*P* = 0.355) or neutrophil/lymphocyte ratio (*P* = 0.751).

CONCLUSION

Neither baseline sarcopenia nor SML affected survival. In addition, baseline sarcopenia was not related to worse treatment toxicity. However, these results must be interpreted with caution due to the limited sample size.

**Key Words:** Sarcopenia; Lean body mass; Skeletal muscle mass; Metastatic colorectal cancer

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Maddalena C, Ponsiglione A, Camera L, Santarpia L, Pasanisi F, Bruzzese D, Panico C, Fiore G, Camardella S, Caramia T, Farinaro A, De Placido S, Carlomagno C. Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study. *World J Clin Oncol* 2021; 12(5): 355-366

**URL:** https://www.wjgnet.com/2218-4333/full/v12/i5/355.htm

**DOI:** https://dx.doi.org/10.5306/wjco.v12.i5.355

**Core Tip:** According to previous studies, sarcopenia is associated with a poorer prognosis in metastatic colorectal cancer (mCRC) patients. We analyzed the prognostic role of sarcopenia in 56 mCRC patients treated with first-line chemotherapy. Neither sarcopenia nor muscle mass loss was significantly associated with survival. Other prospective studies are needed to clarify the role of sarcopenia in mCRC patients. Moreover, greater efforts should be made to diagnose sarcopenia earlier to correct strength and muscle mass, and thus improve patient tolerability to treatment and survival.

**INTRODUCTION**

In medical oncology, the dose of cytotoxic drugs is calculated according to the patient’s body surface area (BSA) using formulae devised in the early twentieth century and validated on a limited number of subjects[1,2]. For instance, the formula proposed by Du Bois*et al*[2], which is routinely used in adult cancer patients, was based on data of only nine patients. Furthermore, individualized dosage of antineoplastic agents based on BSA does not necessarily equate to a patient’s drug exposure because the quantity of active drug circulating in the body and the duration of circulation may vary due to various factors[3,4]. In fact, pharmacokinetic parameters of a particular agent, such as area under the curve and clearance, may differ substantially among patients not only because of genetic factors, pharmacological interactions and the physiological characteristics of patients, but also because of body composition variations that are typical of the natural history of cancer patients[1,5].

The total body mass consists of two major compartments, fat and lean, which are the major sites of distribution of lipophilic and non-lipophilic drugs, respectively[6]. Therefore, the ratio of fat and lean tissue masses could be a better parameter than BSA with which to determine the dose of cytotoxic agents, as it affects metabolism, plasma concentration and the toxicity of chemotherapy drugs[6,7]. Moreover, patients with a similar or identical body weight, BSA or body mass index (BMI) may have a different lean body mass (LBM)[8,9]. Skeletal muscle tissue accounts for most of the LBM and is the predominant source of proteins which are essential for all cell processes[4,10]. People with a low skeletal muscle mass may have a lower volume of drug distribution and reduced protein binding compared to people with a normal muscle mass thereby resulting in a higher plasma drug concentration and worse treatment toxicity[8,11]. The skeletal muscle mass decrease due to physiological ageing or concomitant disease such as neoplasia is defined as “sarcopenia”[12]. In cancer patients, a low LBM and sarcopenia are negative prognostic factors for survival[8,9,13] and for the development of dose-limiting chemotherapy toxicities[6,14] irrespective of disease stage. The aim of the present study was to retrospectively analyze the prevalence of sarcopenia in patients with metastatic colorectal cancer (mCRC) and its prognostic role.

In 2018, the European Working Group on Sarcopenia in Older People 2 published an updated definition that uses low muscle strength as the primary parameter for recognizing sarcopenia, together with additional items of low muscle quantity or quality[15]. However, due to the retrospective nature of our analysis, we used the computed tomography (CT) scans performed at the time of first diagnosis of metastatic disease to evaluate the muscle area, and therefore the muscle quantity, at the level of the third lumbar vertebra.

**MATERIALS AND METHODS**

The primary end-point of this study was to assess the association between baseline sarcopenia, estimated before starting first-line chemotherapy, and overall survival (OS) in mCRC patients. The secondary end-points were: (1) to evaluate the potential correlation of baseline sarcopenia with the objective response rate (ORR) to first-line chemotherapy and with the development of side effects to antineoplastic therapy during the first four cycles of treatment; (2) to investigate the association between skeletal muscle loss (SML) at first disease reassessment and OS; and (3) to examine the relationship between sarcopenia and age, BMI, disease stage at the time of first diagnosis and the neutrophil/lymphocyte ratio (NLR) as an inflammation index.

Our retrospective analysis included 56 mCRC patients who received first-line chemotherapy for metastatic disease from 2014 to 2017 at the Medical Oncology Unit of the Federico II University Hospital. All patients had signed the informed consent document for the use of personal data in the medical record according to the Italian privacy legislation. The study was approved by the panel of scientists proposing the research and by all the collaborators who participated in the research and it was conducted in accordance with the 2013 Declaration of Helsinki.

Computerized scans were performed before starting chemotherapy (baseline) and at first disease reassessment (2-3 mo after starting therapy). The images were analyzed by a subspecialty trained abdominal radiologist. Sarcopenia was assessed using the skeletal mass index [SMI = muscle area in cm2/(height in m2)][16]. The cross-sectional area of all skeletal muscles was calculated at the third lumbar vertebra on pre-contrast axial CT images with a slice thickness of 5 mm, using the open-source Horos software (version 3.3.6)[16,17]. An attenuation threshold ranging from -29 to 150 Hounsfield units was set for muscle tissue[16].

Sarcopenia was defined by Martin SMI cut-offs[8], that combined both sex-specific and BMI cut-offs: 43 cm2/m2 for men with BMI < 25 kg/m2, 53 cm2/m2 for men with BMI ≥ 25 kg/m2 and 41 cm2/m2 for women regardless of BMI. A loss of skeletal muscle mass ≥ 5% from baseline CT to first disease reassessment was considered indicative of a deterioration in muscle condition[18]. Patients’ characteristics were categorized as follows: age (< 70 years *vs* ≥ 70 years), BMI (underweight < 18.5 kg/m2; normal weight 18.5-24.9 kg/m2; overweight 25-30 kg/m2 and obese > 30 kg/m2) and disease stage at the time of first diagnosis (limited *vs* metastatic). A NLR ≥ 3 was considered as an inflammation index[19]. Toxicities were analyzed during the first four cycles of therapy and graded according to the Common Terminology Criteria for Adverse Events version 4.0. Survival was calculated from the date of baseline CT, at the time of metastatic disease diagnosis, to death or until the last outpatient visit. Disease status was assessed using the Response Evaluation Criteria in Solid Tumors version 1.1.

The statistical review of the study was performed by a biomedical statistician. Univariate and multivariate analysis and the calculation of the hazard ratio (95%CI) were carried out according to the Cox regression. Survival curves were estimated using the Kaplan–Meier method. The Chi-squared test was used to correlate sarcopenia and ORR, toxicities, age, BMI, disease stage at the time of first diagnosis and NLR. The statistical analysis was performed using the SPSS version 20.0 software (SPSS Inc.).

**RESULTS**

We examined 56 consecutive mCRC patients who had received first-line chemotherapy and whose CT-scans were available in our archive. Fourteen patients (25%) were sarcopenic at baseline CT scan (7/33 men; 7/23 women). The median age of patients was 67 years (37-85 years) and 20 of the 56 patients (35.7%) were 70 years or older. Five of the 14 sarcopenic patients were 70 years or older. BMI distribution was 0% underweight, 37.5% normal weight, 39.3% overweight and 23.2% obese. SMI varied within each BMI category: 6/21 normal weight patients, 6/22 overweight patients and 2/13 obese patients were sarcopenic at baseline CT scan. Eighteen patients (32.1%) had a NLR ≥ 3. At the time of first diagnosis, 23 patients (41.1%) had II or III stage disease according to the pTNM classification and they subsequently developed metastases; 33 patients (58.9%) received the diagnosis at the metastatic stage. Of the 14 sarcopenic patients at the time of first diagnosis of metastatic disease, 4 had metachronous metastases and 10 had synchronous metastases.

The median follow-up was 26.8 mo (3.8-66.8 mo) and the median OS was 27.2 mo (95%CI: 23.3-37.3) (Figure 1). Sarcopenia was not correlated to either OS (HR, 0.72 95%CI: 0.35-1.47, *P* = 0.362) (Figure 2) or higher toxicity during the first 4 cycles of chemotherapy (*P* = 1.0) (Table 1). Four of the 14 (28.6%) sarcopenic patients and 13 of the 42 (31%) non-sarcopenic patients had at least one reduction in drug dosage due to toxicity during the first four cycles of therapy (*P* = 1.0). Twenty-seven patients (48.2%) had a partial or complete response, the disease was stable in 24 patients (42.8%), and 5 patients (8.9%) had disease progression as best response to first-line treatment. Response rate was not correlated to baseline sarcopenia (*P* = 0.221) (Table 1).

At first disease reassessment, 17 patients had an SML ≥ 5% (30.3%); 3 of these patients were already sarcopenic at baseline CT scan, while 7 patients became sarcopenic. Of these 6 men and 1 woman, 4 were under the age of 70 years; at baseline, 3/7 patients were normal weight, 3/7 were overweight and 1/7 was obese. One normal weight patient became overweight, while one overweight patient became normal weight at first disease reassessment. The median OS of these 7 patients was 27.93 mo, similar to that of the entire study population. Muscle mass loss was not correlated to OS (*P* = 0.961) (Figure 3).

No statistically significant correlation was found between baseline sarcopenia and age (*P* = 1.0), BMI (*P* = 0.728), stage at diagnosis (*P* = 0.355) and NLR (*P* = 0.751) (Table 1).

**DISCUSSION**

Skeletal muscle decrease is generally associated with physiological ageing. The probable mechanism of sarcopenia is an imbalance in muscle protein turnover due to endocrine changes (*e.g.*, reduction of sex hormones and growth factors), age-related cell damage and mitochondrial dysfunction, oxidative stress, low-grade systemic inflammation, physical inactivity and malnutrition[20–23]. In cancer patients the loss of muscle mass can occur earlier than in healthy people due to the synergy between physiologic and tumor factors (*e.g.*, production of inflammatory cytokines that induces a catabolic state)[24]. Depending on histology and disease stage, the prevalence of sarcopenia varies greatly among patients affected by neoplasia; for example, sarcopenia has been diagnosed in 30%-65% of patients with pancreatic neoplasia[25,26]; in 15.9%-66.9% of women with breast cancer[27,28]; in 47.9%-89% of gastric cancer patients[29–31]; in 27.5% of patients with advanced hepatocellular carcinoma[32]; in 52.5%-54.5% of patients with metastatic renal cell carcinoma[33,34]; in 19.4%-39% of patients with colorectal cancer[35,36].

In our study population, the prevalence of sarcopenia was 25%: 14 of the 56 patients were sarcopenic at baseline CT and most of them (9/14, 64%) were under the age of 70 years, which indicates that it is not uncommon to find a low skeletal mass in young adults. In this context, it is notable that Miyamoto *et al*[37] found that young CRC patients (< 65 years) with sarcopenia had a significantly shorter OS than those without sarcopenia, while the prognostic role of sarcopenia was lost in patients above 65 years of age. Consequently, it is also important to assess muscle mass in young CRC patients upon diagnosis, to better define the prognosis of each patient, and possibly to tailor anticancer treatment and improve the correction of sarcopenia. Indeed, various strategies have been reported to improve muscle mass and strength, namely exercise[38,39], dietary supplementation of proteins[40] and long-term intake of omega-3 fatty acids, which have anti-inflammatory and anabolic activities[41].

Clinicians should determine whether patients have sarcopenia not only regardless of age, but also regardless of BMI. In fact, a feature of sarcopenia that differentiates it from cachexia, is that it can occur without a concomitant loss of adipose tissue. In our study, no patient was underweight, and 8 of the 14 (57%) sarcopenic patients were overweight or obese (Figure 4). Notably, not all sarcopenic patients have a low BMI: unlike other causes of muscle loss, sarcopenia can be associated with normal or even excessive body weight, *i.e.*, the so-called “sarcopenic obesity”[8,9]. The loss of muscle tissue can be associated with increased intramuscular fat, which results in a reduction in strength and muscle mass[40]. Martin *et al*[8] found that high weight loss, a low muscle index and low muscle attenuation due to fat infiltration, independently worsened survival in 1473 patients with lung or gastrointestinal cancer. Patients with all three of these poor prognostic variables survived 8.4 mo (95%CI: 6.5 to 10.3) regardless of BMI, in contrast to patients who had none of these features, who survived 28.4 mo (95%CI: 24.2 to 32.6; *P* < 0.001)[8]. In addition, BMI was predictive of survival, with the heaviest patients showing the longest survival. However, obese patients without any risk factorS survived 35.6 mo, which is twice longer than the median survival of the entire population (16.7 mo), while obese patients with three poor prognostic variables survived only 8.5 mo[8].

A low LBM and sarcopenia have been correlated to a worse prognosis and a worse quality of life in patients with solid tumors[6,7,13]. A meta-analysis of 38 studies, involving a total of 7843 patients, showed that subjects with a reduced SMI had a shorter OS, cancer-specific survival and disease-free survival than subjects with a normal SMI[13]. However, it included studies of various tumor types (*e.g.*, pancreaticobiliary cancer, hepatocellular carcinoma and esophageal cancer that have worse outcomes than other malignancies, such as colorectal cancer), disease stages (limited and advanced), therapeutic strategies, imaging techniques and sarcopenia cut-off values.

In our patient cohort undergoing first-line chemotherapy for mCRC, sarcopenia was not related to either survival or response rate. Previous studies reported that low muscle mass was a negative prognostic factor both in resectable[37,42] and in advanced[43–45] colorectal cancer. However, those studies included patients with clinical and disease-related characteristics different to our patients. For example, Vashi *et al*[43] studied patients younger than ours (median age 53.3 years) who were at different disease stages (early and metastatic disease), some of whom had already been treated for metastatic disease. Moreover, they used cut-off values that did not consider gender or BMI in their definition of sarcopenia. Also the reports by Kurk *et al*[44] and Charette *et al*[45] were based on data derived from clinical trials designed for different endpoints, and included patients undergoing maintenance chemotherapy after the first therapeutic line or heavily pretreated patients. The latter two groups of patients have a better and worse prognosis, respectively, than our patients.

Differently, other studies did not find a correlation between basal sarcopenia and survival, but they suggested that muscle mass loss during treatment plays a negative prognostic role. For example, Miyamoto *et al*[18] analyzed 182 Asian patients with unresectable CRC. Female gender (*P* < 0.001) and BMI < 25 kg/m2 (*P* < 0.001) were significantly associated with a lower SMI. There were no significant associations between baseline skeletal muscle mass, progression-free survival (PFS) and OS[18]. However, 22 patients with SML > 5% after first-line chemotherapy had significantly shorter PFS and OS *vs* those without SML (PFS, log-rank *P* = 0.029; OS, log-rank *P* = 0.009)[18]. Sasaki *et al*[46] found sarcopenia in 135 of 219 Asian mCRC patients (mostly male, older, with a lower BMI, lower visceral and subcutaneous fat content and a lower waist circumference than patients without sarcopenia). Baseline sarcopenia was not associated with prognosis, but SML ≥ 9% at 3 mo was associated with a high incidence of adverse events (*P* = 0.01), poor ORR (*P* < 0.01) and poor PFS (*P* = 0.03)[46]. Also Blauwhoff-Buskermolen *et al*[47] observed that the muscle area of 67 patients with mCRC (78% at first-line treatment and 22% at second-line treatment) decreased by 6.1% (95%CI: 28.4% to 23.8%; *P* < 0.001) during 3 mo of chemotherapy. Changes in muscle area were not associated with any treatment dosage modifications (dose reduction, delay or discontinuation), but patients with a muscle loss of 9% or more during treatment had significantly lower survival rates (at 6 mo, 33% *vs* 69% of patients alive; at 1 year, 17% *vs* 49% of patients alive; log-rank *P* = 0.001)[47].

We found no association between muscle loss during first-line treatment and survival, but it is interesting to note that a SML ≥ 5% occurred in 17 patients (30.3%); only 3 of whom were already sarcopenic at baseline CT scan, while 7 patients became sarcopenic during therapy. Chemotherapy probably induces progressive muscle damage both directly *via* a cytotoxic mechanism, and indirectly consequent to a more sedentary lifestyle because of the development of toxicity and asthenia.

In our analysis, sarcopenia was not related to higher toxicity reported during the first four cycles of chemotherapy, but 30.4% of all patients had at least one reduction in drug dosage due to toxicity, which indicates that approximately one-third of our patients did not receive an adequate drug dosage as calculated based on BSA. In this context, it is interesting to refer to the data reported by Prado *et al*[14], who examined 62 patients with stage II/III colorectal cancer receiving adjuvant treatment with 5-fluorouracil (5-FU). Exposure to 5-FU was then normalized per kilogram of LBM. In women, the 5-FU dose/kg LBM varied from 12.8 to 23 mg/kg LBM and, in men, from 12 to 20.1 mg/kg LBM[14]. Levels greater than or equal to 20 mg of 5-FU/kg of LBM were associated with an increased risk of developing dose-limiting toxicities (any grade 3/4 toxicity, dose delay or reduction) at first therapy cycle, especially in women[14]. The population analyzed in the latter study differed greatly from our patients as it included only early-stage colon cancer patients who had undergone surgery on the primary tumor and they were treated with a single adjuvant drug, administered with an obsolete schedule (5-FU and leucovorin by i.v. bolus for 5 d every 28 d); however, these data illustrate how drug exposure varies widely among patients and how this variation affects treatment tolerability.

Other studies investigated the correlation between low muscle mass and worse toxicity during chemotherapy. For instance, Ali *et al*[6] assessed data from one prospective (*n* = 80 patients) and one retrospective study (*n* = 58 patients) that included patients at different stages of CRC, treated with different therapeutic regimens with one or more drugs. They observed that a low LBM was an independent determinant of toxicity and neuropathy in patients administered a FOLFOX-based regimen (5-FU + oxaliplatin) using conventional BSA dosing[6]. Gökyer *et al*[48] evaluated 36 patients with mCRC who received regorafenib. Dose-limiting toxicity (DLT), defined as toxicity requiring dose reduction or drug withdrawal, occurred in 13 of the 23 patients (56.5%) with basal sarcopenia, whereas only 1 of the 13 patients (7.6%) without sarcopenia experienced DLT (*P* = 0.005)[48]. Kurk *et al*[44,49], using data of the randomized phase 3 CAIRO3 study[50], found that sarcopenia at the start of maintenance capecitabine + bevacizumab was not associated with DLT, whereas patients with > 2% SMI loss had a significantly higher risk of DLT. When capecitabine + oxaliplatin + bevacizumab was reintroduced due to disease progression, 25% of patients started the treatment at a reduced dose and most of them were patients with previous SMI loss[49]. Interestingly, after drug dose adjustment, no further DLT was observed in the subgroup of patients with SMI loss[49].

Currently, data on the prognostic and predictive role of sarcopenia are based mostly on retrospective studies or on clinical trials designed for other endpoints. Conflicting results highlight the need to investigate further the role of low muscle mass in cancer patients. Indeed, there is a need for prospective studies of more homogeneous populations in terms of age, sex, tumor histology, stage of disease, treatment setting, and mono- or polychemotherapy regimens. In the future, clinicians might evaluate the body composition of cancer patients before starting chemotherapy in order to select the drug (*e.g.* lipophilic, hydrophilic, immunotherapy or biological) with the shortest regime (for example, shortening induction therapy in favor of a weakened therapy in sarcopenic patients), the most adequate dosage, and ancillary support strategies (*e.g.* exercise, specific nutrition supplements, drugs, *etc.*).

**CONCLUSION**

In our study, neither baseline sarcopenia nor muscle mass loss during first-line chemotherapy influenced survival in mCRC patients. Moreover, baseline sarcopenia did not worsen treatment toxicities during first-line chemotherapy. However, these results must be interpreted with caution given the limited sample size. Further prospective studies are needed to investigate the actual role of sarcopenia in prognosis and therapeutic decision-making. Greater efforts should be made to diagnose sarcopenia upon cancer diagnosis to correct strength and muscle mass as early as possible and thus improve the patient’s tolerability to treatment and survival.

**ARTICLE HIGHLIGHTS**

***Research background***

People with a low skeletal muscle mass, defined as “sarcopenia”, may have a lower volume of drug distribution and reduced protein binding compared to people with a normal muscle mass thereby resulting in a higher plasma drug concentration and worse treatment toxicity. In cancer patients, sarcopenia is considered a negative prognostic factor for survival and for the development of dose-limiting chemotherapy toxicities.

***Research motivation***

Pharmacokinetic parameters of a given drug, such as area under the curve and clearance, may differ substantially among patients depending on body composition. The ratio of fat to lean tissue mass could be a better tool than body surface area with which to determine the dose of cytotoxic agents as it affects metabolism, plasma concentration and the toxicity of drugs.

***Research objectives***

The primary end-point of this study was to assess the association between baseline sarcopenia, evaluated before starting first-line chemotherapy, and overall survival in metastatic colorectal cancer patients. The secondary end-points were to investigate: (1) the potential correlation of baseline sarcopenia with the objective response rate to first-line chemotherapy and with the development of side effects during the first four cycles of treatment; (2) the association between skeletal muscle loss (SML) at first disease reassessment and overall survival (OS); and (3) the relationship between sarcopenia and age, body mass index (BMI), disease stage at the time of first diagnosis and the neutrophil/lymphocyte ratio as an inflammation index.

***Research methods***

Computed tomography (CT)-scans were performed before starting chemotherapy and at the first disease reassessment. Sarcopenia was assessed using the skeletal mass index [SMI = muscle area in cm2/(height in m2)] calculated at the L3 vertebra. Sarcopenia was defined by Martin SMI cut-offs that combined both sex-specific and BMI cut-offs: 43 cm2/m2 for men with BMI < 25 kg/m2, 53 cm2/m2 for men with BMI ≥ 25 kg/m2, and 41 cm2/m2 for women regardless of BMI. OS and objective response rate were evaluated. Toxicities were analyzed during the first four cycles of therapy and graded according to Common Terminology Criteria for Adverse Events version 4.0. A loss of skeletal muscle mass ≥ 5% was considered indicative of deterioration in muscle condition.

***Research results***

The prevalence of sarcopenia was 25%: 14 of the 56 patients were sarcopenic at baseline CT and most of them (9/14, 64%) were under the age of 70 years, which indicates that it is not uncommon to find a low skeletal mass in young adults. No patient was underweight, and 8 of the 14 (57%) sarcopenic patients were overweight or obese. Sarcopenia was not correlated to overall survival (*P* = 0.362), to higher toxicities reported during the first 4 cycles of chemotherapy (*P* = 1) or to response to treatment (*P* = 0.221). At the first disease reassessment, a SML ≥ 5% was found in 17 patients (30.3%) 3 of whom were already sarcopenic at baseline CT scan, while 7 became sarcopenic. SML was not correlated to overall survival (*P* = 0.961).

***Research conclusions***

Although this is a negative study, our results must be interpreted with caution given the limited sample size. Moreover, the body composition of cancer patients should be evaluated before starting chemotherapy to better select the drug (*e.g.* lipophilic, hydrophilic, immunotherapy or biological) with the shortest regime (for example, shortening induction therapy in favor of a weakened therapy in sarcopenic patients), the most adequate dosage, and ancillary support strategies (*e.g.* exercise, specific nutrition supplements, drugs, *etc.*).

***Research perspectives***

There is a need for prospective studies of more homogeneous populations in terms of age, sex, tumor histology, stage of disease, treatment setting, and mono- or polychemotherapy regimens, to investigate the actual role of sarcopenia in prognosis and therapeutic decisions. Greater efforts should be made to diagnose sarcopenia upon cancer diagnosis in order to correct strength and muscle mass as early as possible and thus improve the patient’s treatment tolerability and survival.

**ACKNOWLEDGEMENTS**

We thank Jean Ann Gilder (Scientific Communication Srl., Naples, Italy) for language assistance.

**REFERENCES**

1 **Mathijssen RH**, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? *Oncologist* 2007; **12**: 913-923 [PMID: 17766650 DOI: 10.1634/theoncologist.12-8-913]

2 **Du Bois D**, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. *Nutrition* 1989; **5**: 303-11; discussion 312-3 [PMID: 2520314]

3 **Baker SD**, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. *J Natl Cancer Inst* 2002; **94**: 1883-1888 [PMID: 12488482 DOI: 10.1093/jnci/94.24.1883]

4 **Sawyer M**, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. *Invest New Drugs* 2001; **19**: 171-177 [PMID: 11392451 DOI: 10.1023/a:1010639201787]

5 **Gusella M**, Toso S, Ferrazzi E, Ferrari M, Padrini R. Relationships between body composition parameters and fluorouracil pharmacokinetics. *Br J Clin Pharmacol* 2002; **54**: 131-139 [PMID: 12207632 DOI: 10.1046/j.1365-2125.2002.01598.x]

6 **Ali R**, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, Mollevi C, Senesse P. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. *Cancer Med* 2016; **5**: 607-616 [PMID: 26814378 DOI: 10.1002/cam4.621]

7 **Prado CM**, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. *Cancer Chemother Pharmacol* 2011; **67**: 93-101 [PMID: 20204364 DOI: 10.1007/s00280-010-1288-y]

8 **Martin L**, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. *J Clin Oncol* 2013; **31**: 1539-1547 [PMID: 23530101 DOI: 10.1200/JCO.2012.45.2722]

9 **Prado CM**, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. *Lancet Oncol* 2008; **9**: 629-635 [PMID: 18539529 DOI: 10.1016/S1470-2045(08)70153-0]

10 **Tsai S**. Importance of lean body mass in the oncologic patient. *Nutr Clin Pract* 2012; **27**: 593-598 [PMID: 22898746 DOI: 10.1177/0884533612457949]

11 **Hopkins JJ**, Sawyer MB. A review of body composition and pharmacokinetics in oncology. *Expert Rev Clin Pharmacol* 2017; **10**: 947-956 [PMID: 28649898 DOI: 10.1080/17512433.2017.1347503]

12 **Cruz-Jentoft AJ**, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010; **39**: 412-423 [PMID: 20392703 DOI: 10.1093/ageing/afq034]

13 **Shachar SS**, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. *Eur J Cancer* 2016; **57**: 58-67 [PMID: 26882087 DOI: 10.1016/j.ejca.2015.12.030]

14 **Prado CM**, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. *Clin Cancer Res* 2007; **13**: 3264-3268 [PMID: 17545532 DOI: 10.1158/1078-0432.CCR-06-3067]

15 **Cruz-Jentoft AJ**, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019; **48**: 16-31 [PMID: 30312372 DOI: 10.1093/ageing/afy169]

16 **Mourtzakis M**, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. *Appl Physiol Nutr Metab* 2008; **33**: 997-1006 [PMID: 18923576 DOI: 10.1139/H08-075]

17 **Shen W**, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB, Heshka S. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. *J Appl Physiol (1985)* 2004; **97**: 2333-2338 [PMID: 15310748 DOI: 10.1152/japplphysiol.00744.2004]

18 **Miyamoto Y**, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, Hiyoshi Y, Iwagami S, Yoshida N, Watanabe M, Baba H. Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer. *PLoS One* 2015; **10**: e0129742 [PMID: 26069972 DOI: 10.1371/journal.pone.0129742]

19 **Feliciano EMC**, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, Xiao J, Alexeeff S, Corley D, Weltzien E, Castillo AL, Caan BJ. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. *JAMA Oncol* 2017; **3**: e172319 [PMID: 28796857 DOI: 10.1001/jamaoncol.2017.2319]

20 **Rier HN**, Jager A, Sleijfer S, Maier AB, Levin MD. The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. *Oncologist* 2016; **21**: 1396-1409 [PMID: 27412391 DOI: 10.1634/theoncologist.2016-0066]

21 **Argilés JM**, Busquets S, Felipe A, López-Soriano FJ. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. *Int J Biochem Cell Biol* 2005; **37**: 1084-1104 [PMID: 15743680 DOI: 10.1016/j.biocel.2004.10.003]

22 **Muscaritoli M**, Lucia S, Molfino A, Cederholm T, Rossi Fanelli F. Muscle atrophy in aging and chronic diseases: is it sarcopenia or cachexia? *Intern Emerg Med* 2013; **8**: 553-560 [PMID: 22773188 DOI: 10.1007/s11739-012-0807-8]

23 **Jeejeebhoy KN**. Malnutrition, fatigue, frailty, vulnerability, sarcopenia and cachexia: overlap of clinical features. *Curr Opin Clin Nutr Metab Care* 2012; **15**: 213-219 [PMID: 22450775 DOI: 10.1097/MCO.0b013e328352694f]

24 **Bennani-Baiti N**, Davis MP. Cytokines and cancer anorexia cachexia syndrome. *Am J Hosp Palliat Care* 2008; **25**: 407-411 [PMID: 18403577 DOI: 10.1177/1049909108315518]

25 **Chan MY**, Chok KSH. Sarcopenia in pancreatic cancer - effects on surgical outcomes and chemotherapy. *World J Gastrointest Oncol* 2019; **11**: 527-537 [PMID: 31367272 DOI: 10.4251/wjgo.v11.i7.527]

26 **Tan BH**, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. *Clin Cancer Res* 2009; **15**: 6973-6979 [PMID: 19887488 DOI: 10.1158/1078-0432.CCR-09-1525]

27 **Zhang XM**, Dou QL, Zeng Y, Yang Y, Cheng ASK, Zhang WW. Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review. *BMC Cancer* 2020; **20**: 172 [PMID: 32131764 DOI: 10.1186/s12885-020-6645-6]

28 **Prado CM**, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. *Clin Cancer Res* 2009; **15**: 2920-2926 [PMID: 19351764 DOI: 10.1158/1078-0432.CCR-08-2242]

29 **Rinninella E**, Cintoni M, Raoul P, Pozzo C, Strippoli A, Bria E, Tortora G, Gasbarrini A, Mele MC. Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. *Clin Nutr* 2020; **39**: 2045-2054 [PMID: 31718876 DOI: 10.1016/j.clnu.2019.10.021]

30 **Lee JS**, Kim YS, Kim EY, Jin W. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer. *PLoS One* 2018; **13**: e0202700 [PMID: 30125312 DOI: 10.1371/journal.pone.0202700]

31 **Sugiyama K**, Narita Y, Mitani S, Honda K, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Ando M, Tajika M, Muro K. Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer. *Anticancer Res* 2018; **38**: 5859-5866 [PMID: 30275211 DOI: 10.21873/anticanres.12928]

32 **Mir O**, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, Ropert S, Vidal M, Pol S, Chaussade S, Goldwasser F. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. *PLoS One* 2012; **7**: e37563 [PMID: 22666367 DOI: 10.1371/journal.pone.0037563]

33 **Antoun S**, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. *Ann Oncol* 2010; **21**: 1594-1598 [PMID: 20089558 DOI: 10.1093/annonc/mdp605]

34 **Huillard O**, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, Ropert S, Delongchamps NB, Zerbib M, Goldwasser F. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. *Br J Cancer* 2013; **108**: 1034-1041 [PMID: 23462722 DOI: 10.1038/bjc.2013.58]

35 **van Vledder MG**, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. *Br J Surg* 2012; **99**: 550-557 [PMID: 22246799 DOI: 10.1002/bjs.7823]

36 **Thoresen L**, Frykholm G, Lydersen S, Ulveland H, Baracos V, Prado CM, Birdsell L, Falkmer U. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. *Clin Nutr* 2013; **32**: 65-72 [PMID: 22695408 DOI: 10.1016/j.clnu.2012.05.009]

37 **Miyamoto Y**, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, Hiyoshi Y, Iwagami S, Yoshida N, Yoshida M, Watanabe M, Baba H. Sarcopenia is a Negative Prognostic Factor After Curative Resection of Colorectal Cancer. *Ann Surg Oncol* 2015; **22**: 2663-2668 [PMID: 25564158 DOI: 10.1245/s10434-014-4281-6]

38 **Maddocks M**, Murton AJ, Wilcock A. Improving muscle mass and function in cachexia: non-drug approaches. *Curr Opin Support Palliat Care* 2011; **5**: 361-364 [PMID: 21934503 DOI: 10.1097/SPC.0b013e32834bdde3]

39 **Lenk K**, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. *J Cachexia Sarcopenia Muscle* 2010; **1**: 9-21 [PMID: 21475693 DOI: 10.1007/s13539-010-0007-1]

40 **Cruz-Jentoft AJ**, Dawson Hughes B, Scott D, Sanders KM, Rizzoli R. Nutritional strategies for maintaining muscle mass and strength from middle age to later life: A narrative review. *Maturitas* 2020; **132**: 57-64 [PMID: 31883664 DOI: 10.1016/j.maturitas.2019.11.007]

41 **Di Girolamo FG**, Situlin R, Mazzucco S, Valentini R, Toigo G, Biolo G. Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. *Curr Opin Clin Nutr Metab Care* 2014; **17**: 145-150 [PMID: 24500439 DOI: 10.1097/MCO.0000000000000032]

42 **van Vugt JLA**, Coebergh van den Braak RRJ, Lalmahomed ZS, Vrijland WW, Dekker JWT, Zimmerman DDE, Vles WJ, Coene PLO, IJzermans JNM. Impact of low skeletal muscle mass and density on short and long-term outcome after resection of stage I-III colorectal cancer. *Eur J Surg Oncol* 2018; **44**: 1354-1360 [PMID: 29914788 DOI: 10.1016/j.ejso.2018.05.029]

43 **Vashi PG**, Gorsuch K, Wan L, Hill D, Block C, Gupta D. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. *PLoS One* 2019; **14**: e0218761 [PMID: 31220163 DOI: 10.1371/journal.pone.0218761]

44 **Kurk SA**, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Creemers GM, Erdkamp FLG, de Jongh FE, Kint PAM, Poppema BJ, Radema SA, Simkens LHJ, Tanis BC, Tjin-A-Ton MLR, Van Der Velden A, Punt CJA, Koopman M, May AM. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial. *Cancer Med* 2020; **9**: 1033-1043 [PMID: 31850687 DOI: 10.1002/cam4.2787]

45 **Charette N**, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, Hendlisz A. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials. *BMC Cancer* 2019; **19**: 134 [PMID: 30744591 DOI: 10.1186/s12885-019-5319-8]

46 **Sasaki S**, Oki E, Saeki H, Shimose T, Sakamoto S, Hu Q, Kudo K, Tsuda Y, Nakashima Y, Ando K, Akagi Y, Kakeji Y, Baba H, Maehara Y. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A). *Int J Clin Oncol* 2019; **24**: 1204-1213 [PMID: 31062115 DOI: 10.1007/s10147-019-01460-8]

47 **Blauwhoff-Buskermolen S**, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, Verheul HM. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. *J Clin Oncol* 2016; **34**: 1339-1344 [PMID: 26903572 DOI: 10.1200/JCO.2015.63.6043]

48 **Gökyer A**, Küçükarda A, Köstek O, Hacıoğlu MB, Sunal BS, Demircan NC, Uzunoğlu S, Solak S, İşsever K, Çiçin I, Erdoğan B. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib. *Clin Transl Oncol* 2019; **21**: 1518-1523 [PMID: 30868388 DOI: 10.1007/s12094-019-02080-4]

49 **Kurk S**, Peeters P, Stellato R, Dorresteijn B, de Jong P, Jourdan M, Creemers GJ, Erdkamp F, de Jongh F, Kint P, Simkens L, Tanis B, Tjin-A-Ton M, Van Der Velden A, Punt C, Koopman M, May A. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. *J Cachexia Sarcopenia Muscle* 2019; **10**: 803-813 [PMID: 31094083 DOI: 10.1002/jcsm.12436]

50 **Simkens LH**, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. *Lancet* 2015; **385**: 1843-1852 [PMID: 25862517 DOI: 10.1016/S0140-6736(14)62004-3]

**Footnotes**

**Institutional review board statement:** The study was approved by the panel of scientists proposing the research and by all the collaborators who participated in the research.

**Informed consent statement:** Informed written consent was obtained from the patients for publication of this report.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** December 26, 2020

**First decision:** January 18, 2021

**Article in press:** March 18, 2021

**Specialty type:** Oncology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Bordonaro M, Wang YH **S-Editor:** Zhang H **L-Editor:** Webster JR **P-Editor:** Wu YXJ

**Figure Legends**

****

**Figure 1 Overall survival.**

****

**Figure 2 Overall survival according to baseline sarcopenia.**

****

**Figure 3 Overall survival according to muscle mass loss.**

****

**Figure 4 Representative examples of two obese patients with different** **skeletal mass index values.** A: The patient is a 56-year-old man with body mass index (BMI) = 32.91 kg/m2 and normal skeletal mass index (SMI) value = 62.70 cm2/m2; B: The patient is a 61-year-old woman showing BMI = 32.54 kg/m2 and reduced SMI value = 39.45 cm2/m2.

**Table 1 Correlation between sarcopenia, age, body mass index, stage at diagnosis, neutrophil/lymphocyte ratio, toxicity and response to treatment, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Sarcopenia** | ***P* value** |
| **Total** | **No** | **Yes** |
| Age | 1 |
| ≥ 70 yr | 20 (35.7) | 15 (35.7) | 5 (35.7) |  |
| BMI (kg/m2) | 0.728 |
| 18.5-24.9  | 21 (37.5) | 15 (35.7) | 6 (42.9) |  |
| 25-30 | 22 (39.3) | 16 (38.1) | 6 (42.9) |  |
| > 30 | 13 (23.2) | 11 (26.2) | 2 (14.3) |  |
| Stage at diagnosis | 0.355 |
| TNM II/III3 | 23 (41.1) | 19 (45.2) | 4 (28.6) |  |
| TNM IV | 33 (58.9) | 23 (54.8) | 10 (71.4) |  |
| NLR | 0.751 |
| ≥ 3 | 18 (32.1) | 13 (31) | 5 (35.7) |  |
| Toxicity during the first 4 chemotherapy cycles |  |
| At least one dose reduction | 17 (30.4) | 13 (31) | 4 (28.6) | 1 |
| Diarrhea G ≥ 2 | 10 (17.9) | 8 (19) | 2 (14.3) | 1 |
| Neutropenia G ≥ 3/4 | 11 (19.6) | 8 (19) | 3 (21.4) | 1 |
| Response to treatment | 0.221 |
| Partial/complete response | 27 (48.2) | 18 (42.9) | 9 (64.3) |  |

BMI: Body mass index; NLR: Neutrophil/lymphocyte ratio.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**